Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors


MHLW (Japan) approves Jardiance (empagliflozin) for the treatment of chronic kidney disease (CKD) – Nippon Boehringer Ingelheim

Written by | 26 Feb 2024

MHLW (Japan) approved on February 9 Nippon Boehringer Ingelheim’s SGLT2 inhibitor Jardiance (empagliflozin) for the treatment of chronic kidney disease (CKD) </p. Jardiance has been available in Japan… read more.

FDA approves Jardiance (empagliflozin) for the treatment of adults with chronic kidney disease – Boehringer + Eli Lilly

Written by | 28 Sep 2023

Boehringer Ingelheim and Eli Lilly and Company announced that the FDA has approved Jardiance (empagliflozin) 10 mg tablets to reduce the risk of sustained decline in estimated glomerular… read more.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.


You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.